Introduction to NASH

Nonalcoholic steatohepatitis (NASH) affects approximately 25 million people in the
US1 and it is projected that by 2020, NASH will overtake hepatitis C
as the leading cause of liver transplants2. Currently, biopsy is the
gold standard for the diagnosis of NASH. However, biopsy may be subject to sampling
problems that can confound the results, in addition to surgical costs, risk, and
inconvenience for the patient.

Identifying High-Risk NASH Patients is Imperative

F3-F4 stage of liver fibrosis has been identified as the most significant independent
risk factor for mortality in NASH patients3,4

NASH-related cirrhosis is becoming a more common indication for liver transplantation3

When and in whom to initiate HCV therapy. American Association for the Study of
Liver Diseases and the Infectious Diseases Society of America Web site. http://www.hcvguidelines.org/evaluate/when-whom.
Last updated July 6, 2016. Accessed July 24, 2017.